Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: July 03, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 339 miles
UCLA Medicine Hematology and Oncology
Los Angeles,CA

VISITS: Number of visits unavailable


NCT ID: NCT04171700

PARP Inhibitor Rucaparib in Advanced Breast Cancer That Tests Positive for BRCA or Other Mutations

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes (LODESTAR) Scientific Title

To look at the safety, effects (good and bad), and anti-tumor activity of the PARP inhibitor rucaparib (Rubraca®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have been treated with at least one standard of care therapy but no more than two lines of chemotherapy; and who have inherited (or whose tumor tests positive for) one of the several mutations listed below.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rucaparib (Rubraca®), by mouth, twice a day, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rucaparib (Rubraca®) is a PARP inhibitor: it blocks poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA. It is approved to treat women with advanced ovarian cancer whose tumors have a BCRA 1 or BRCA 2 mutation. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">People with an inherited BRCA 1 or BRCA 2 mutation and whose tumor is HER2 negative (HER2-) tumor are not eligible for this trial. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of advanced cancer.</li> <li class="seamTextUnorderedListItem">To take part in this study your tumor must test positive for, or you must have inherited, one of these mutations: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04171700' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rubraca.com/?utm_source=google&utm_medium=cpc&utm_term=rucaparib&utm_campaign=Branded_Alone_GS_EX&gclid=Cj0KCQiAsbrxBRDpARIsAAnnz_OQBEzA3MVbEPTW02l-js4vH6_2yBSOiLDwbWxO914whM6BmwDeWMsaAse7EALw_wcB' target='_blank'>Drug Company Information Page: Rubraca® (Rucaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/02/04/mbc-news-8/' target='_blank'>Metastatic Trial Talk: Get the Latest News on PARP Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncologypro.esmo.org/oncology-in-practice/anti-cancer-agents-and-biological-therapy/parp-inhibition-and-dna-damage-response-ddr/parp-inhibitors/clinical-activity/breast-cancer/ongoing-developments' target='_blank'>ESMO Oncology: PARP Inhibitors in Breast Cancer (HRR Gene Mutations)</a> </li></ul>
See more